Solution containing IGF-1
US5783559A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 16, 1995 |
| Grant date | Jul 21, 1998 |
| Priority date | — |
| Expiry date | Oct 16, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to solutions containing IGF-1 or any functional analogue thereof in which pH is 5.5 to 6.5, preferably 5.7 to 6.2. The amount of phosphate as buffer substance should be in a concentration of less than 50 mmol/L Preferably the formulation is an aqueous solution of IGF-1 and phosphate as buffer substance in a concentration of 5 to 50 mmole or more preferably 5-20 mmol/L, e.g. 10 mmol/L. The solution should be isotonic. The solution gives a reduced pain upon subcutaneous injection. The invention also relates to a process for preparation of the formulation by mixing IGF-1 or any functional analogue thereof with a buffer substance giving pH 5.5 to 6.5 and an isotonic agent. It also relates to a method for treatment of a patient in need of IGF-1 or any functional analogue thereof by administering the claimed formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.